KONEXBiotech & Pharma456570

Imgt

₩13,000▼ 2.91%2026-10-02 close

Market Cap

₩68.4B

Turnover

₩2,307,870

Volume

176 shares

Shares out.

5.3M

PER

—

PBR

—

EPS

—

Dividend Yield

—

PER, PBR and dividend yield are calculated from the latest confirmed results (EPS, BPS, dividend per share) and the current share price · Prices as of the 2026-10-02 close

Report overview

FUS Technology Enters FDA Pivotal Trial

IMGT has secured both FDA Breakthrough Device Designation and IDE approval for its pivotal trial, placing its focused ultrasound-based pancreatic cancer therapy on a clear global commercialization track.

1
Consecutive FDA BDD & IDE in 2025: First globally to receive Breakthrough Device Designation (Feb 2025) and pivotal trial IDE (Nov 2025) for a FUS device in pancreatic cancer.
2
Encouraging exploratory trial data: Seoul National University Hospital exploratory trial showed 60% tumor response rate (vs. 33% control), hazard ratio 0.44, and median OS extension of 5.1 months.
3
Multi-center pivotal trial patient enrollment to begin H1 2026 at five confirmed sites: three US centers (including Brigham & Women's/Harvard) and two Korean hospitals.
4
KOSDAQ transfer listing targeted for Q3 2026: Technology evaluation application filed in December 2025, with potential for a valuation re-rating upon market transfer.
5
Persistent financial fragility: Shareholders' equity approximately -KRW 24.4bn (full capital impairment) as of 2024; net loss expanded ~228% YoY in 2025; KRW 14.7bn 3rd-party capital raise executed in April 2025.

Business structure

IMGT was founded in April 2010 in Seongnam, Gyeonggi-do, as a focused ultrasound (FUS)-based drug delivery platform company, co-led by CEO Lee Hak-jong (concurrent professor at Bundang Seoul National University Hospital) and CEO/CTO Son Geon-ho.

Its core technology, ChemoSono Therapy®, employs focused ultrasound to temporarily create micropores in tumor cell membranes, dramatically enhancing intratumoral drug penetration without the need for exogenous microbubble agents—regarded as a world-first approach.

The lead pipeline, IMD10, targets concurrent use with first-line pancreatic cancer chemotherapy (FOLFIRINOX) and has entered the pivotal clinical trial stage.

Additional pipeline assets include IMP101 (nanoparticle-based hepatic artery embolization device) and IMP301 (improved drug candidate for breast cancer), while the obesity treatment device IMD10F remains in preclinical development, and indication expansions into biliary cancer, sarcoma, and musculoskeletal diseases are planned.

Revenue is minimal given the R&D-stage profile; cumulative funding stands at approximately KRW 33bn from Series A–C financing rounds plus approximately KRW 17bn in government R&D project support.

The primary global benchmark is NovoCure (USA), whose electromagnetic tumor treatment field device exceeded KRW 70bn in annual revenue after FDA approval and reached a post-listing market cap of over KRW 4tn.

Internationally, HistoSonics (FUS-based tumor treatment, ~KRW 300bn Series C) and SonoTera (ultrasound-responsive DDS, ~KRW 80bn Series A) also command significant investor attention.

No direct domestic competitor in FUS-based pancreatic cancer treatment currently exists, providing IMGT with an early-mover positional advantage.

Recent trends

Based on disclosed financial data, IMGT recorded a consolidated operating loss of approximately KRW 5.44bn and a net loss of approximately KRW 11.24bn for fiscal year 2024. Total shareholders' equity stood at approximately -KRW 24.44bn (full capital impairment), with total liabilities of approximately KRW 30.19bn.

For fiscal year 2025, FnGuide data indicate that operating loss was essentially flat YoY, while net loss expanded approximately 228% YoY; this likely reflects a combination of rising financial costs associated with redeemable convertible preferred shares and other non-cash charges.

To address the funding gap, the company raised approximately KRW 14.7bn in April 2025 through a third-party allotment capital increase—issuing 166,912 common shares and 961,537 redeemable convertible preferred shares—drawing participation from K2 Expedeo Fund 3, HIP Fund 5 KONEX Scale-up New Technology, IBK, and JB Woori Capital.

The defining events of 2025 were FDA Breakthrough Device Designation (February) and FDA pivotal IDE approval on November 22, 2025—the first instance of a Korean oncology medical device company receiving a pivotal IDE, and the world's first for a FUS device in pancreatic cancer.

In December 2025, the company applied for a technology evaluation for a KOSDAQ transfer listing, targeting completion by Q3 2026.

As of June 5, 2026, the share price stands at KRW 11,800 (+3.24% DoD) with a market capitalization of approximately KRW 100bn; however, daily trading volume of approximately KRW 3.3mn underscores extreme KONEX illiquidity.

Outlook

Patient enrollment is expected to commence in H1 2026 at five confirmed clinical sites—three in the US (including Brigham & Women's Hospital/Harvard and additional oncology centers) and two in Korea (Seoul National University Hospital and Bundang Seoul National University Hospital).

The pivotal trial results will be the decisive driver of enterprise value; a successful readout would trigger a De Novo marketing authorization application in the US, with BDD status enabling expedited FDA review.

A KOSDAQ technology-exception transfer listing targeted by Q3 2026, if successful, would resolve the structural illiquidity of KONEX and potentially attract institutional inflows and a valuation re-rating.

In the US, the company plans to establish a local subsidiary and commence outreach to 72 Tier-1 hospitals; CPT3 reimbursement code approval—anticipated around Q3 2027—would mark the entry into a sustained US revenue generation phase.

Ongoing discussions with Boston Scientific, GE Healthcare, and a major domestic ADC developer represent optionality for non-dilutive licensing income.

However, executing multiple simultaneous initiatives while operating in full capital deficit remains a significant financial challenge, and with pivotal trial data readout not anticipated before 2027–2028, near-term price catalysts will center on clinical milestone updates and KOSDAQ listing progress.

Bull factors

World-First Technology with Dual FDA Validation

IMGT secured, for the first time globally, both FDA Breakthrough Device Designation (February 2025) and a pivotal IDE approval (November 2025) for a FUS device in pancreatic cancer—also the first Korean oncology medical device company to achieve pivotal IDE status.

This dual regulatory recognition constitutes meaningful external validation of IMGT's core technology. Supporting these approvals, exploratory trial data demonstrated a 60% tumor response rate (vs. 33% in controls), HR 0.44, and a 5.1-month median OS extension—a credible scientific foundation for the pivotal study.

BDD status also positions the company favorably for expedited FDA review and reimbursement pathway negotiations.

Strategic Partnership Optionality and KOSDAQ Listing Catalyst

Discussions reportedly ongoing with Boston Scientific and GE Healthcare could unlock non-dilutive funding via upfront payments and milestone receipts upon deal execution. Joint development discussions with a major domestic ADC developer further broaden the technology's potential commercial scope.

A KOSDAQ technology-exception transfer listing in Q3 2026 would eliminate KONEX's extreme illiquidity, substantially improving investor accessibility and enabling institutional inflows.

Relative to recent successful KOSDAQ technology-exception biotech listings, IMGT's profile as a clinical-stage company with dual FDA validation presents a plausible case for a meaningful valuation re-rating.

High Unmet Need in Pancreatic Cancer and Large Addressable Market

Pancreatic cancer carries a five-year survival rate below 10%, and conventional chemotherapy is fundamentally limited by poor intratumoral drug penetration. IMGT's FUS technology addresses this structural therapeutic gap through a device-based approach that has no direct competitor in the segment.

NovoCure's post-FDA approval trajectory—exceeding KRW 70bn in annual revenue and a market cap of over KRW 4tn—provides a benchmark for the commercial potential of mechanism-adjacent medical devices.

Planned indication expansions into breast cancer, biliary cancer, and sarcoma, as well as potential ADC combination regimens, further expand the total addressable market.

Bear factors

Full Capital Deficit and Accelerating Cash Burn

Total shareholders' equity stood at approximately -KRW 24.4bn as of 2024 (full capital impairment), and net loss expanded approximately 228% YoY in 2025.

With negligible revenue given the R&D-stage profile, cash outflows are expected to accelerate as the pivotal trial progresses alongside US subsidiary establishment and KOSDAQ listing preparation.

Despite the April 2025 KRW 14.7bn capital raise, the likelihood of additional fundraising rounds cannot be excluded, creating ongoing dilution risk for common shareholders.

The complex capital structure—including redeemable convertible preferred shares—contains further latent dilution that must be factored into investment analysis.

Clinical Failure and Trial Delay Risk

Positive exploratory results do not guarantee replication in a large-scale randomized pivotal study, which demands statistically more rigorous standards.

Multi-center, multi-country trials are susceptible to enrollment rate disparities, protocol deviations, and IRB approval delays that can push back timelines materially.

Clinical failure or absence of meaningful interim efficacy signals would simultaneously undermine the KOSDAQ transfer listing schedule and the company's core valuation premise. Given the small-cap KONEX profile, negative clinical events can trigger disproportionately sharp share price dislocations.

KONEX Extreme Illiquidity and Listing Uncertainty

Daily trading volume of approximately KRW 3.3mn as of the reference date makes meaningful trading practically impossible for most investors, imposing severe entry and exit friction.

The outcome of the technology evaluation for a KOSDAQ technology-exception listing is binary; any failure or delay would materially weaken the valuation rationale currently embedded in the share price.

Even after a positive technology evaluation, significant hurdles remain—including preliminary listing review and institutional bookbuilding—before actual KOSDAQ listing is achieved.

The challenge of meeting listing financial requirements while in a state of full capital impairment adds further uncertainty to the listing timeline.

Risk factors

Clinical & Regulatory Risk

Failure to meet primary endpoints (overall survival or tumor response rate) in the FDA pivotal trial would preclude a De Novo marketing authorization application and fundamentally erode the company's valuation basis.

Additional data requests or protocol modification requirements during FDA interactions could substantially extend timelines and escalate clinical costs.

Managing dual regulatory pathways—both the Korean MFDS and US FDA—demands robust regulatory capabilities from a small organization, and capacity constraints could affect the overall clinical schedule.

Financial & Liquidity Risk

Executing simultaneous pivotal trial activities and US market expansion while operating in full capital deficit creates vulnerability to operational continuity risks if capital market conditions deteriorate.

Mandatory redemption or conversion pressure from redeemable convertible preferred shares can impose substantial dilution on common shareholders at inopportune times.

The extreme KONEX illiquidity constrains access to market-based financing, and any delay in a KOSDAQ transfer listing would intensify financial pressure, potentially necessitating costly debt financing or further equity dilution.

Macro & Competitive Risk

Deterioration in global monetary and liquidity conditions can directly dampen investor sentiment toward clinical-stage biotech ventures and compress sector multiples for KOSDAQ biotech broadly.

International FUS and ultrasound-responsive DDS peers—including HistoSonics and SonoTera—have secured substantial capital and are advancing their own programs, while large medical device incumbents entering adjacent technology spaces cannot be excluded.

USD/KRW exchange rate movements directly affect the cost of US clinical operations; dollar appreciation would amplify expenditure burdens and accelerate cash depletion.

Overall view

IMGT has established clear technical leadership and a meaningful regulatory moat by becoming the first company globally to secure both FDA BDD and a pivotal IDE approval for a FUS device in pancreatic cancer.

Exploratory trial data—60% tumor response rate, HR 0.44, and 5.1-month median OS extension—provide credible scientific support for the ongoing pivotal study, and a KOSDAQ technology-exception transfer listing in Q3 2026 could serve as a valuation re-rating catalyst.

However, the full capital deficit and sharply accelerating net losses in 2025 underscore near-term financial fragility, with non-trivial dilution risk from ongoing and prospective capital raises.

Pivotal trial data readout is not anticipated before 2027–2028, leaving clinical milestone updates and partnership announcements as the primary near-term price drivers and making the tension between technology optionality and financial risk the central consideration for positioning.

The structural illiquidity of KONEX imposes high friction costs on both entry and exit, making an observational stance—monitoring pivotal trial enrollment progress, interim data signals, and KOSDAQ listing developments—the most appropriate posture at this stage.

Sources

Korea Exchange (KRX) — Prices · Market Cap · Volume
FSS electronic disclosure system (DART) — Financial statements · Dividend filings

Show 10 more articles and sources

Report written 2026-06-05 · Data as of 2026-06-05

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.